Fresenius Group Overview

Results Center

Q3/2017 Results

Fresenius reports another strong quarter and confirms guidance

  • Ongoing strong sales growth
  • Continued healthy earnings growth
  • 2017 Group guidance confirmed
  • Strong Cashflow
  • Strategic position further strengthened

Selected Key Figures Q3/2017

1 Constant currency

2 Before acquisition-related expenses

3 Before acquisition-related expenses; before expenditures for further development of biosimilars business